# US 10,946,083 B2 · Anti-microbial immunomodulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,083 B2
- Document ID: US10946083B2
- Status: Granted
- Kind: B2
- Application number: 16/264,040
- Filed: 2019-01-31
- Published: 2019-08-15
- Granted: 2021-03-16
- Earliest claimed: 2014-05-02
- Assignees: Qu Biologies Inc.
- Applicants: Qu Biologies Inc.
- Inventors: Harold David Gunn; Salim Dhanji; David W. Mullins
- Web page: https://patentgrep.com/patent/US10946083B2

## CPC

- A61K 39/0266: {Klebsiella}
- A61K 39/0258: {Escherichia}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/541: {Mucosal route}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.

## Claims

### Claim 1

A method of modulating an immune system in a vertebrate host for the prophylactic [or therapeutic]treatment of infection by a first microbial pathogen in a target tissue, the method comprising:
administering to the vertebrate host an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen, wherein:
the antigenic determinants are selected from the group consisting of whole cells or cell wall extracts;
the first microbial pathogen is a microbial lung pathogen that is not a Klebsiella pneumonia, Streptococcus pneumonia, Pseudomonas aeruginosa or a viral lung pathogen, and the second heterologous microbial pathogen is a Klebsiella pneumonia, and the target tissue is the lung; and,
wherein the administering comprises administering successive doses of the formulation at a dosage interval of at least one hour, so that two or more doses are administered over a period from 2 days to 1 month, over a dosage duration of at least one week.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first microbial pathogen is Moraxella catarrhalis, Mycoplasma pneumoniae, or Haemophilus influenza.

### Claim 3 (depends on 1)

The method of claim 1, wherein the host is a human patient.

### Claim 4 (depends on 2)

The method of claim 2, wherein the host is a human patient.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antigenic determinants comprise whole cells.

### Claim 6 (depends on 2)

The method of claim 2, wherein the antigenic determinants comprise whole cells.

### Claim 7 (depends on 3)

The method of claim 3, wherein the antigenic determinants comprise whole cells.

### Claim 8 (depends on 4)

The method of claim 4, wherein the antigenic determinants comprise whole cells.

### Claim 9 (depends on 5)

The method of claim 5, wherein the whole cells are killed.

### Claim 10 (depends on 6)

The method of claim 6, wherein the whole cells are killed.

### Claim 11 (depends on 7)

The method of claim 7, wherein the whole cells are killed.

### Claim 12 (depends on 8)

The method of claim 8, wherein the whole cells are killed.

### Claim 13 (depends on 5)

The method of claim 5, wherein the whole cells are attenuated.

### Claim 14 (depends on 6)

The method of claim 6, wherein the whole cells are attenuated.

### Claim 15 (depends on 7)

The method of claim 7, wherein the whole cells are attenuated.

### Claim 16 (depends on 8)

The method of claim 8, wherein the whole cells are attenuated.

### Claim 17 (depends on 1)

The method of claim 1, wherein the antigenic determinants comprise cell wall extracts.

### Claim 18 (depends on 2)

The method of claim 2, wherein the antigenic determinants comprise cell wall extracts.

### Claim 19 (depends on 3)

The method of claim 3, wherein the antigenic determinants comprise cell wall extracts.

### Claim 20 (depends on 4)

The method of claim 4, wherein the antigenic determinants comprise cell wall extracts.